Echelon-inc

Echelon Biosciences成立于1997年10月3日，總部坐落于在美國(guó)猶他州。從1997到2004，EBI主要用于政府的補(bǔ)助金以及產(chǎn)品的銷售收入來資助其研究工作。2005年初，EBI的依特鈉Zentaris購(gòu)買 （NAS：AEZS）的MEP抗感染，PI3激酶小分子程序，目錄業(yè)務(wù)，與科學(xué)專業(yè)。2007年末，前沿科學(xué)公司（FSI）在洛根，猶他州購(gòu)買了EBI， 專業(yè)從事卟啉和硼化學(xué)。自公司成立以來以來，EBI保留了開發(fā)研究試劑脂質(zhì)新的檢測(cè)方法。不斷開拓**，從而推動(dòng)**研究的新發(fā)型。

Echelon Biosciences是美國(guó)杰出**學(xué)產(chǎn)品供應(yīng)商，專業(yè)提供各種抗體、分析檢測(cè)試劑盒、抑制劑等產(chǎn)品，尤其擅長(zhǎng)以細(xì)胞信號(hào)、脂類代謝和標(biāo)記物研究為主的相關(guān)產(chǎn)品。為研究**諸如癌癥、糖尿病、炎癥、感染和心腦血管**專家提供**有效工具。

Echelon Biosciences產(chǎn)品線

PI3-Kinase PI3-激酶

Echelon Biosciences可提供PI3-Kinase 實(shí)驗(yàn)解決全套方案，從分析服務(wù)到實(shí)驗(yàn)用抗體、酶和抑制劑等，**滿足科研需求。

Lysolipids 血溶性脂類

Lysolipid Pathway                                            Synthetic Lysophosphatidic Acid (LPA)
◆ Inhibitors 抑制劑系列                                  ◆ Labeled 標(biāo)記物系列
◆ Ligands 配體系列                                        ◆ Ligands 配體系列
◆ Analogs 類似物系列                                    ◆ Saturated 底物系列
                                                                         ◆ Unsaturated 不飽和系列 

Sphingolipids 鞘脂類

Synthetic Sphingolipids

◆ Sphingosine 鞘氨醇                           ◆ Ceramide 神經(jīng)酰胺

◆ Sphingosine 1 Phosphate (S1P ) 鞘氨醇磷酸酯     ◆ Sphingomyelin 鞘磷脂

◆ FTY720P 

Autotaxin(ATX) 自分泌運(yùn)動(dòng)因子

Echelon Biosciences是世界上唯壹完整**提供Autotaxin(ATX) 和Autotaxin(ATX) 相關(guān)試劑的供應(yīng)商。

Echelon Biosciences目的在于進(jìn)一步發(fā)展的脂質(zhì)的細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)的關(guān)鍵代謝酶的科學(xué)，它提供了對(duì)癌癥，心血管****，糖尿病，炎癥，感染的潛在的**和診斷發(fā)展的新的和可行的目標(biāo)。

Echelon Biosciences為生命科學(xué)社區(qū)提供的產(chǎn)品包括：

抗體            分析檢測(cè)試劑盒

抑制劑           細(xì)胞信號(hào)產(chǎn)品

脂類代謝          標(biāo)記物

              Z-R015    Anti-huVps34 （Class III PI3-Kinase） Antibody for IP
抗體            Z-R016    Anti-huVps34 （Class III PI3-Kinase） Antibody for WB

               K-1000    PI3-K ELISA Kit
試劑盒       K-1000S    PI3-K ELISA: Pico Assay
                  K-1100    PI3-K Fluorescence Polarization Kit
                  K-1300    PI3-K AlphaScreen®
                  K-2700S    TRueFRET PI3-K Activity Assay
                  K-3000    Class III PI3-K ELISA Kit

              P27-18H    PI3-K （p-110 alpha/p85 alpha） Active Enzyme
酶               P28-10H    PI3-K （p-110 beta/p85 alpha） Active Enzyme
              B-0021    Resveratrol （Class IA PI3-K Inhibitor）
抑制劑        B-0222    Wortmannin （PI3-Kinase Inhibitor）
                   B-0294    PI3-Kinase Inhibitor （LY294002）
                   B-0301    PI3-Kinase Gamma Inhibitor 1 （AS605240）
                   B-0302    PI3-Kinase Gamma Inhibitor 2 （AS604850
                   B-0303    PI3-Kinase Alpha Inhibitor 1 （PI-103）
                   B-0304    PI3-Kinase Alpha Inhibitor 2

Echelon Biosciences Incorporated (EBI) was incorporated under the laws of the state of Utah as Echelon Research Laboratories, Inc. on October 3, 1997. Initially, Echelon Biosciences EBI was formed from a project under the Center for Cell Signaling, a State of Utah Center of Excellence, with the aim to further the science of lipid cell signaling and critical metabolic enzymes, which provide new and viable targets for the development of potential drugs and diagnostics for cancer, diabetes, inflammation, infections, and cardiovascular disease.

From 1997 through 2004, Echelon Biosciences EBI primarily used government grants and product sales revenues to fund its research efforts. In early 2005, EBI was purchased by Aeterna Zentaris (NAS: AEZS) for its MEP anti-infectives, PI3-Kinase small molecule program, catalog business, and scientific expertise. In late 2007, Frontier Scientific Incorporated (FSI) based in Logan, Utah purchased EBI. Specializing in porphyrin and boron chemistry, FSI opened the doors for expanded research.

Since 1997, Echelon Biosciences EBI has retained its commitment to developing novel assays and reagents for lipid research and beyond. At EBI’s core is the desire to innovate, thus pushing medicinal research to new limits. We look forward to providing scientists around the world with the tools they need to cure human disease states for years to come and we welcome any suggestions about how we can better do so.